Nanobody-LOOP2 peptide conjugates recruited anti-HBsAg vaccine-induced antibodies to EGFR+ cancer cells, triggering ADCP and CDC for cell elimination — a novel way to leverage population-wide vaccine immunity for cancer treatment.
Vaccine → cancer killerExisting anti-hepatitis B vaccine antibodies in billions of vaccinated people can be redirected to kill cancer cells using nanobody-peptide conjugates
What the researchers found
Nanobody-LOOP2 conjugates recruited vaccine-induced anti-HBsAg antibodies to EGFR+ cancer cells, evoking ADCP and CDC. PEG spacer minimally affected ADCP but significantly impacted CDC. Proof-of-concept for vaccine-based ARM therapeutics.
Why it matters
Over 2 billion people have HBV vaccine-induced antibodies. Redirecting this existing immunity against cancer requires no new immune priming.
How the study worked
Chemoenzymatic synthesis of EGFR nanobody-LOOP2 peptide conjugates with varying PEG spacers, anti-HBsAg antibody recruitment validation, ADCP and CDC functional assays, and structure-activity relationship analysis.
What this study cannot tell us
In vitro proof-of-concept. Anti-HBsAg antibody levels vary among vaccinated individuals. EGFR-specific but could be adapted. In vivo efficacy not tested.
How to read the evidence
Proof-of-concept in vitro study. Innovative concept with functional validation but needs in vivo testing.
When this study was published
Published in 2025.
The bigger picture
This represents a paradigm shift: using existing population-wide vaccine immunity as a ready-made anticancer weapon through rationally designed peptide-nanobody conjugates.
Questions still open
- Would anti-HBsAg antibody titers in vaccinated patients be sufficient for clinical efficacy?
- Could this approach leverage other common vaccine-induced antibodies (e.g., anti-tetanus)?
- How would this compare to bispecific antibodies for cancer cell killing?
Common questions
How does a hepatitis vaccine help fight cancer?
Is this available as a treatment?
Read the original research
Chemoenzymatic Synthesis of Nanobody-Peptide Conjugates Capable of Harnessing HBV Vaccine-Induced Antibodies for Cancer Immunotherapy.
Bioconjugate chemistry, 37(1), 11-19
Citation
Hong, Haofei; Zhang, Zijiang; Wang, Zheng; Zhang, Zongqin; Zhang, Linpei; Wu, Zhimeng. (2026). Chemoenzymatic Synthesis of Nanobody-Peptide Conjugates Capable of Harnessing HBV Vaccine-Induced Antibodies for Cancer Immunotherapy.. Bioconjugate chemistry, 37(1), 11-19. https://doi.org/10.1021/acs.bioconjchem.5c00413